[go: up one dir, main page]

MX2008014337A - Agentes y metodos para imagenologia. - Google Patents

Agentes y metodos para imagenologia.

Info

Publication number
MX2008014337A
MX2008014337A MX2008014337A MX2008014337A MX2008014337A MX 2008014337 A MX2008014337 A MX 2008014337A MX 2008014337 A MX2008014337 A MX 2008014337A MX 2008014337 A MX2008014337 A MX 2008014337A MX 2008014337 A MX2008014337 A MX 2008014337A
Authority
MX
Mexico
Prior art keywords
agent
patient
detecting
nir813
cancer
Prior art date
Application number
MX2008014337A
Other languages
English (en)
Inventor
Wei Wang
Chun Li
Marites P Melancon
Juri Gelovani
Jeffrey Myers
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2008014337A publication Critical patent/MX2008014337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0033—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through a sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
    • C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
    • C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La descripción incluye una composición que incluye un poli(ácido L-glutámico) y un pigmento NIRF. También incluye un método que incluye proporcionar a una pluralidad de células un agente formador de imágenes que incluye poli(ácido L-glutámico), un pigmento NIFR y luego formar la imagen de las células para detectar el agente formador de imágenes. Además incluye un agente de contraste funcional doble que incluye un agente MRI conjugado con un gente formador de imágenes ópticas. Se proporciona un método para detectar cáncer que incluye inyectar un agente de contraste funcional doble en un paciente y realizar tanto un MRI como un barrido óptico. La presencia del agente puede indicar cáncer. Se proporciona el método para detectar cáncer al inyectar PG-DTPA-Gd-NIR813 en el paciente, luego detectar la presencia o ausencia de Gd en la célula o tejido del paciente y detectar la presencia o ausencia de NIR813 en la célula o tejido del paciente. La presencia de Gd y NIR813 puede indicar cáncer.
MX2008014337A 2006-05-12 2007-05-11 Agentes y metodos para imagenologia. MX2008014337A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74718006P 2006-05-12 2006-05-12
US81929706P 2006-07-07 2006-07-07
PCT/US2007/068783 WO2007134236A2 (en) 2006-05-12 2007-05-11 Imaging agents and methods

Publications (1)

Publication Number Publication Date
MX2008014337A true MX2008014337A (es) 2009-06-17

Family

ID=38694735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014337A MX2008014337A (es) 2006-05-12 2007-05-11 Agentes y metodos para imagenologia.

Country Status (6)

Country Link
US (1) US20100290997A1 (es)
EP (1) EP2018163A4 (es)
AU (1) AU2007249226A1 (es)
CA (1) CA2653244A1 (es)
MX (1) MX2008014337A (es)
WO (1) WO2007134236A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
WO2009012288A2 (en) 2007-07-17 2009-01-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging
WO2009133545A2 (en) 2008-04-30 2009-11-05 Ben Gurion University Of The Negev Research And Development Authority Vascular delivery systems
WO2010101298A1 (ja) * 2009-03-04 2010-09-10 国立大学法人 東京大学 蛍光ｍｒｉプローブ
US10167319B2 (en) 2010-05-29 2019-01-01 Ben-Gurion University Of Negev Research & Development Authority Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
EP2736506B1 (en) 2011-07-26 2018-09-05 University Of Southern California Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer
US9675620B2 (en) 2011-07-26 2017-06-13 University Of Southern California MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
US8798716B1 (en) * 2011-11-03 2014-08-05 Solstice Corporation Fiducial markers and related methods
CN102964603B (zh) * 2012-10-29 2014-07-16 浙江大学宁波理工学院 合成以笼型八聚(γ-氨丙基)硅倍半氧烷为核的树枝状化合物三氟乙酸盐的方法
WO2014165766A1 (en) * 2013-04-05 2014-10-09 The Trustees Of The University Of Pennsylvania Quantification of in vivo metabolite
AU2019339428A1 (en) * 2018-09-15 2021-04-08 The Board Of Regents Of The University Of Texas System Dual modality ups nanoprobes for tumor acidosis imaging
WO2020204640A1 (ko) * 2019-04-05 2020-10-08 연세대학교 산학협력단 대사체를 유효성분으로 포함하는 신규한 조영제 조성물
KR102381029B1 (ko) * 2019-04-05 2022-03-31 연세대학교 산학협력단 대사체를 유효성분으로 포함하는 신규한 조영제 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6228344B1 (en) * 1997-03-13 2001-05-08 Mallinckrodt Inc. Method of measuring physiological function
US6458511B1 (en) * 2000-06-07 2002-10-01 Kodak Polychrome Graphics Llc Thermally imageable positive-working lithographic printing plate precursor and method for imaging
US6844139B2 (en) * 2003-01-03 2005-01-18 Kodak Polychrome Graphics, Llc Method for forming a lithographic printing plate
WO2005017539A2 (en) * 2003-08-14 2005-02-24 The General Hospital Corporation Imaging pathology

Also Published As

Publication number Publication date
EP2018163A4 (en) 2009-07-15
US20100290997A1 (en) 2010-11-18
AU2007249226A1 (en) 2007-11-22
WO2007134236A3 (en) 2008-07-24
CA2653244A1 (en) 2007-11-22
EP2018163A2 (en) 2009-01-28
WO2007134236A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
MX2008014337A (es) Agentes y metodos para imagenologia.
Hesketh et al. Magnetic resonance imaging is more sensitive than PET for detecting treatment-induced cell death–dependent changes in glycolysis
WO2010091049A3 (en) Diagnosis and treatment of cancer
EP2480565A4 (en) PEPTIDOMIMETIC MACROCYCLES
WO2008015599A3 (en) A method of in vivio detection and/or diagnosis of cancer using fluorescence based dna image cytometry
WO2010042815A3 (en) Vhh antibody fragments for use in the detection and treatment of cancer
BR112014013544A2 (pt) materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata
WO2005072780A3 (en) Cellular labeling for nuclear magnetic resonance techniques
TW200735890A (en) Compositions and methods for increasing insulin sensitivity
WO2009135178A3 (en) Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
WO2010033597A3 (en) Methods for detecting overexpression of sparc and therapeutic and diagnostic methods relating to same
WO2009134435A3 (en) Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
WO2006099019A8 (en) Methods and composition related to in vivo imaging of gene expression
Tian et al. A two‐photon tracer for glucose uptake
Yue et al. Inducible graphene oxide probe for high-specific tumor diagnosis
WO2004028449A3 (en) Azulene dimer-quenched, near-infrared fluorescent probes
RU2012148816A (ru) Метод диагностики для определения клеток ex vivo
Wu et al. Rational Design of an Activatable Near‐Infrared Fluorogenic Platform for In Vivo Orthotopic Tumor Imaging and Resection
WO2008005942A3 (en) Activatable probes and methods of use
WO2009133362A3 (en) Agents for detecting and imaging cell death
TN2012000590A1 (en) Apparatus, method and computer-readable storage medium for evaluating a physiological condition of a patient
Wang et al. Molecular Imaging of Ovarian Follicles and Tumors With Near‐Infrared II Bioconjugates
Du et al. Nanomedicines in the treatment of liver fibrosis: a review
Lee et al. A bright blue fluorescent dextran for two-photon in vivo imaging of blood vessels
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal